Arrowhead Pharmaceuticals, Inc. ARWR · Stock Open Arrowhead Pharmaceuticals, Inc. in new tab
Arrowhead Pharmaceuticals, Inc. Analysis (ARWR)
Is Arrowhead Pharmaceuticals, Inc. a good investment? Arrowhead Pharmaceuticals, Inc. (ARWR) is currently trading at 86.01 USD. Market analysts have a consensus price target of 104.27 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 46.76. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: Arrowhead Pharmaceuticals, Inc. is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -4.56.
Investor FAQ
Does Arrowhead Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Arrowhead Pharmaceuticals, Inc.?
Arrowhead Pharmaceuticals, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -2.27.
Company Profile
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
| Split Date | Split Ratio to 1 |
|---|---|
| Jan. 15, 2004 | 0.020000 |
| Nov. 17, 2011 | 0.100000 |
Community Discussion